

Spinal Muscular Atrophy (SMA)

A Study Evaluating the Effectiveness and Safety of Risdiplam Administered in Pediatric Patients With Spinal Muscular Atrophy Who Experienced a Plateau or Decline in Function After Gene Therapy

Trial Status Recruiting	Trial Runs In 1 Countries	Trial Identifier NCT05861999 2023-505161-81-00 BN44621
-----------------------------------	-------------------------------------	---

The source of the below information is the publicly available website *ClinicalTrials.gov*. It has been summarised and edited into simpler language.

Trial Summary:

This is an open-label, single-arm, multicenter clinical study to evaluate the effectiveness and safety of risdiplam administered in pediatric participants with SMA and 2 SMN2 copies who previously received onasemnogene abeparvovec and experience a plateau or decline in function. Participants to be enrolled are children <2 years of age genetically diagnosed with SMA.

Hoffmann-La Roche Sponsor	Phase 4 Phase
NCT05861999 2023-505161-81-00 BN44621 Trial Identifiers	

Eligibility Criteria:

Gender All	Age >=3 Months & <= 24 Months	Healthy Volunteers No
----------------------	---	---------------------------------